@article{eda3af735549437194e83d758be61487,
title = "Sleep quality and outcome of exposure therapy in adults with social anxiety disorder",
abstract = "Introduction: Poor sleep is prevalent among individuals with social anxiety disorder (SAD) and may negatively affect exposure therapy outcomes. Poor sleep may impair memory and learning, and thus compromise fear extinction learning thought to take place in exposure therapy. We examined poor sleep as a predictor of exposure therapy outcomes for SAD and the moderating role of d-cycloserine (DCS) on this relationship. Methods: Participants were 152 individuals with a primary diagnosis of SAD. As part of a randomized clinical trial evaluating the efficacy of DCS for enhancing the effects of exposure therapy, they completed self-report baseline measure of sleep quality, and self-report sleep diaries assessing sleep duration (total sleep time [TST]) and sleep quality the nights before and after treatment sessions. Results: Poorer baseline sleep quality was significantly associated with slower improvement over time and worse symptom outcomes at the end of treatment and follow-up after controlling for baseline symptoms of depression and social anxiety. Greater TST the night before treatment predicted lower SAD symptoms at the next session, after controlling for symptoms at the previous session. There was no relation between prior or subsequent night sleep quality on symptoms at the next session. No associations were moderated by DCS. Conclusions: We replicated and extended findings indicating that poor sleep quality is associated with poorer exposure therapy outcomes for SAD. Assessing for sleep difficulties before treatment initiation and incorporating sleep interventions into treatment may enhance exposure therapy outcomes for SAD.",
keywords = "cognitive behavioral therapy, d-cycloserine, exposure therapy, sleep difficulties, sleep quality, social anxiety disorder, treatment outcomes",
author = "Dutcher, {Christina D.} and Dowd, {Sheila M.} and Zalta, {Alyson K.} and Taylor, {Daniel J.} and David Rosenfield and Alexander Perrone and Otto, {Michael W.} and Pollack, {Mark H.} and Hofmann, {Stefan G.} and Smits, {Jasper A.J.}",
note = "Funding Information: Dr. Smits reports grants from the National Institute of Mental Health during the conduct of the study; personal fees from Big Health Ltd., personal fees from Aptinyx, personal fees from Elsevier, personal fees from American Psychological Association, personal fees from Oxford University Press, grants from National Institute on Drug Abuse, and grants from Cancer Prevention and Research Institute of Texas outside the submitted work. Dr. Dowd reports financial support for consultation for The Wellness Network and research grants from the NIH and Janssen Pharmaceuticals outside of the submitted work. Dr. Zalta's effort on the current study was partially supported by a career development award from the NIMH (K23MH103394). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr. Rosenfield reports stipends from various journals for duties related to their Editorial Boards, and fees from Rosenfield Analytics for data analysis and statistical consulting. In addition, he reports grants from the National Institutes of Health, the DOD, and the Cancer Prevention and Research Institute of Texas for research outside the submitted work. Dr. Otto reports personal fees from Big Health Ltd., outside the submitted work. Dr. Pollack reports grants from NIMH during the conduct of the study. Outside of the submitted work, Dr. Pollack reports financial support for consultation for Almatica, Aptinyx, Big Health Ltd., Brackett, Brainsway, and EMA Wellness Seelos, and Sophren Therapeutics; grant support from Janssen; other from Argus, Doyen, Mensante, Mindsite, and Targia; and currently an employee of Myriad Neuroscience. Dr. Hofmann reports grants from NIH/NIMH during the conduct of the study; financial support from the Alexander von Humboldt Foundation (as part of the Humboldt Prize), NIH/NCCIH(R01AT007257), NIH/NIMH (R01MH099021, U01MH108168), and the James S. McDonnell Foundation 21st Century Science Initiative in Understanding Human Cognition— Special Initiative. He receives compensation for his work as editor from SpringerNature and the Association for Psychological Science, and as an advisor from the Palo Alto Health Sciences Otsuka Pharmaceuticals, and for his work as a Subject Matter Expert from John Wiley & Sons Inc., and SilverCloud Health Inc. He also receives royalties and payments for his editorial work from various publishers. Other authors have nothing to disclose. Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC",
year = "2021",
month = nov,
doi = "10.1002/da.23167",
language = "English (US)",
volume = "38",
pages = "1182--1190",
journal = "Anxiety",
issn = "1091-4269",
publisher = "Wiley-Blackwell",
number = "11",
}